While two anti-PCSK9 monoclonal antibodies, namely alirocumab and evolocumab, were approved for use to treat patients with familial hypercholesterolemia and CVD and ongoing clinical trial of the siRNA targeting PCSK9 named inclisiran yielded favorable outcomes30, drug development for anti-IDOL therapies is still at the preclinical stage. Here, PCSK9 is linked to familial hypercholesterolemia.